Regenxbio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
Current Price
—
GoodMoat Value
$8.23
Profile
Valuation (TTM)
Market Cap—
P/E—
EV—
P/B—
Shares Out—
P/Sales—
Revenue—
EV/EBITDA—
Regenxbio Inc (RGNX) Stock Analysis
Market Cap—
Current Price—
P/E Ratio—
Forward P/E—
PEG Ratio—
EPS—
Book Value—
P/B Ratio—
RGNX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Debt: 224M
Revenue
35M
FY19
155M
FY20
470M
FY21
113M
FY22
90M
FY23
83M
FY24
170M
FY25
Net Income
—
FY19
—
FY20
128M
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Did you know?
RGNX's revenue grew at a 30.0% CAGR over the last 6 years.
Regenxbio Inc (RGNX) Financial Summary
Regenxbio Inc (RGNX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ..
..
RGNX Key Financial Metrics
| Metric | Value |
|---|
RGNX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $35.23M | $-94.73M |
| FY20 | $154.57M | $-111.25M |
| FY21 | $470.35M | $127.84M |
| FY22 | $112.72M | $-280.32M |
| FY23 | $90.24M | $-263.49M |
| FY24 | $83.33M | $-227.10M |
| FY25 | $170.44M | $-193.88M |
Regenxbio Inc (RGNX) Valuation
Based on GoodMoat's DCF model, Regenxbio Inc has a fair value estimate of $8.23.
About Regenxbio Inc
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.